KEAP1 and chronic kidney disease: Therapeutic targeting of the GSK3β mediated Keap1-independent regulation of Nrf2 in renal tubules by GSK3β knockout or by existing FDA approved agents with GSK3β inhibitory activity, like low-dose lithium is able to mitigate AKI to CKD transition.